Effects of Nicotinamide Adenine Dinucleotide on Older Patients with Heart Failure
Reviews in Cardiovascular Medicine · 21.08.2024 · 25 (8)
DOI: 10.31083/j.rcm2508297 ↗Kurz gefasst
Fachartikel in der Zeitschrift Reviews in Cardiovascular Medicine, online erschienen am 21.08.2024. Verfasst von Zuowei Pei und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, 100…. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National High Level Hospital Clinical Research Funding, Knature Company.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Heart failure (HF) is the main cause of death in middle-aged and older people and is characterized by high morbidity, high mortality, a high rehospitalization rate, and many high-risk groups. Nicotinamide adenine dinucleotide (NAD+) is widely present in the mitochondria of cardiomyocytes and maintains the redox balance in the body, which can effectively treat HF. We sought to evaluate whether NAD+ therapy has some clinical efficacy in patients with HF.
Methods
Based on using conventional drugs to treat HF, patients (n = 60) were randomized 1:1 to saline and 50 mg NAD+ with 50 mL of normal saline for 7 days. The baseline characteristics of patients before and after treatment and cardiac function (N-terminal pro B-type natriuretic peptide (NT-proBNP) level and left ventricular ejection fraction (LVEF) value) were analyzed. Serological analysis (sirtuin-1 (SIRT1), sirtuin-3 (SIRT3), sirtuin-6 (SIRT6), reactive oxygen species (ROS), and endothelin) was also performed.
Results
Among the 60 patients with HF who were treated with NAD+ for 7 days, the improvement rate in NT-proBNP levels and LVEF values was better than in the saline group, although not statistically significant. These patients were more likely to benefit from NAD+ because of higher levels of anti-oxidative stress (SIRT1, SIRT3, SIRT6, and ROS) and anti-endothelial injury (endothelin) than those in the saline control group.
Conclusions
According to the results of this study, it is believed that 7 days of NAD+ injections has a positive effect on improving cardiac function, oxidative stress, and endothelial injury in patients with HF compared with the saline control. Clinical Trial Registration: Chinese Clinical Trial Registry (http://www.chictr.org.cn/) ChiCTR2300074326; retrospectively registered on 3 August 2023.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, 100730 Beijing, China.
- Department of Cardiology, Central Hospital of Dalian University of Technology, 116033 Dalian, Liaoning, China.
- Department of Internal Medicine, Affiliated Zhong Shan Hospital of Dalian University, 116001 Dalian, Liaoning, China.
Förderung
- National High Level Hospital Clinical Research Funding
- Knature Company
Zitieren
APA
Pei, Z., Dong, M., Meng, X., Yao, W., Guo, Y., & Wang, F. (2024). Effects of Nicotinamide Adenine Dinucleotide on Older Patients with Heart Failure. Reviews in Cardiovascular Medicine, 25(8). https://doi.org/10.31083/j.rcm2508297
Vancouver
Pei Z, Dong M, Meng X, Yao W, Guo Y, Wang F. Effects of Nicotinamide Adenine Dinucleotide on Older Patients with Heart Failure. Reviews in Cardiovascular Medicine. 2024;25(8). doi:10.31083/j.rcm2508297
BibTeX
@article{Pei2024,
author = {Pei, Zuowei and Dong, Min and Meng, Xuyang and Yao, Wei and Guo, Ying and Wang, Fang},
title = {Effects of Nicotinamide Adenine Dinucleotide on Older Patients with Heart Failure},
journal = {Reviews in Cardiovascular Medicine},
year = {2024},
volume = {25},
number = {8},
doi = {10.31083/j.rcm2508297}
}
EUVIMED